After US$20 Million Win, Chinese Biotech Harbour BioMed Shifts Focus to Larger Patent Battle
Shanghai-based Harbour BioMed has secured a US$20 million damages award against US pharmaceutical giant Amgen in a patent dispute, prompting the company to redirect resources toward another intellectual property case with significantly larger financial implications.